16-3740185-G-T

Variant summary

Our verdict is Benign. The variant received -14 ACMG points: 0P and 14B. BP4_StrongBP6_ModerateBA1

The NM_004380.3(CREBBP):​c.4133+214C>A variant causes a intron change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.466 in 152,068 control chromosomes in the GnomAD database, including 18,734 homozygotes. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Benign (★).

Frequency

Genomes: 𝑓 0.47 ( 18734 hom., cov: 33)

Consequence

CREBBP
NM_004380.3 intron

Scores

2

Clinical Significance

Benign criteria provided, single submitter B:1

Conservation

PhyloP100: -1.26

Publications

15 publications found
Variant links:
Genes affected
CREBBP (HGNC:2348): (CREB binding protein) This gene is ubiquitously expressed and is involved in the transcriptional coactivation of many different transcription factors. First isolated as a nuclear protein that binds to cAMP-response element binding protein (CREB), this gene is now known to play critical roles in embryonic development, growth control, and homeostasis by coupling chromatin remodeling to transcription factor recognition. The protein encoded by this gene has intrinsic histone acetyltransferase activity and also acts as a scaffold to stabilize additional protein interactions with the transcription complex. This protein acetylates both histone and non-histone proteins. This protein shares regions of very high sequence similarity with protein p300 in its bromodomain, cysteine-histidine-rich regions, and histone acetyltransferase domain. Mutations in this gene cause Rubinstein-Taybi syndrome (RTS). Chromosomal translocations involving this gene have been associated with acute myeloid leukemia. Alternative splicing results in multiple transcript variants encoding different isoforms. [provided by RefSeq, Feb 2009]
CREBBP Gene-Disease associations (from GenCC):
  • Rubinstein-Taybi syndrome
    Inheritance: AD Classification: DEFINITIVE Submitted by: ClinGen, Illumina
  • Rubinstein-Taybi syndrome due to CREBBP mutations
    Inheritance: AD Classification: DEFINITIVE, STRONG Submitted by: Labcorp Genetics (formerly Invitae), Ambry Genetics, G2P
  • Menke-Hennekam syndrome 1
    Inheritance: AD Classification: STRONG Submitted by: Ambry Genetics, Labcorp Genetics (formerly Invitae)

Genome browser will be placed here

ACMG classification

Classification was made for transcript

Our verdict: Benign. The variant received -14 ACMG points.

BP4
Computational evidence support a benign effect (BayesDel_noAF=-1.11).
BP6
Variant 16-3740185-G-T is Benign according to our data. Variant chr16-3740185-G-T is described in ClinVar as Benign. ClinVar VariationId is 1225321.Status of the report is criteria_provided_single_submitter, 1 stars.
BA1
GnomAd4 highest subpopulation (AFR) allele frequency at 95% confidence interval = 0.716 is higher than 0.05.

Transcripts

RefSeq

Gene Transcript HGVSc HGVSp Effect Exon rank MANE Protein UniProt
CREBBPNM_004380.3 linkc.4133+214C>A intron_variant Intron 24 of 30 ENST00000262367.10 NP_004371.2

Ensembl

Gene Transcript HGVSc HGVSp Effect Exon rank TSL MANE Protein Appris UniProt
CREBBPENST00000262367.10 linkc.4133+214C>A intron_variant Intron 24 of 30 1 NM_004380.3 ENSP00000262367.5 Q92793-1

Frequencies

GnomAD3 genomes
AF:
0.466
AC:
70783
AN:
151950
Hom.:
18689
Cov.:
33
show subpopulations
Gnomad AFR
AF:
0.722
Gnomad AMI
AF:
0.311
Gnomad AMR
AF:
0.473
Gnomad ASJ
AF:
0.480
Gnomad EAS
AF:
0.543
Gnomad SAS
AF:
0.486
Gnomad FIN
AF:
0.319
Gnomad MID
AF:
0.475
Gnomad NFE
AF:
0.325
Gnomad OTH
AF:
0.456
We have no GnomAD4 exomes data on this position. Probably position not covered by the project.
GnomAD4 genome
AF:
0.466
AC:
70886
AN:
152068
Hom.:
18734
Cov.:
33
AF XY:
0.465
AC XY:
34571
AN XY:
74338
show subpopulations
African (AFR)
AF:
0.723
AC:
29968
AN:
41464
American (AMR)
AF:
0.473
AC:
7234
AN:
15282
Ashkenazi Jewish (ASJ)
AF:
0.480
AC:
1663
AN:
3466
East Asian (EAS)
AF:
0.544
AC:
2808
AN:
5166
South Asian (SAS)
AF:
0.487
AC:
2353
AN:
4828
European-Finnish (FIN)
AF:
0.319
AC:
3366
AN:
10568
Middle Eastern (MID)
AF:
0.480
AC:
141
AN:
294
European-Non Finnish (NFE)
AF:
0.325
AC:
22118
AN:
67978
Other (OTH)
AF:
0.451
AC:
951
AN:
2110
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.502
Heterozygous variant carriers
0
1764
3527
5291
7054
8818
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Genome Het
Genome Hom
Variant carriers
0
624
1248
1872
2496
3120
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
Alfa
AF:
0.367
Hom.:
17395
Bravo
AF:
0.485
Asia WGS
AF:
0.529
AC:
1842
AN:
3478

ClinVar

Significance: Benign
Submissions summary: Benign:1
Revision: criteria provided, single submitter
LINK: link

Submissions by phenotype

not provided Benign:1
Jun 26, 2018
GeneDx
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

Computational scores

Source: dbNSFP v4.3

Name
Calibrated prediction
Score
Prediction
BayesDel_noAF
Benign
-1.1
CADD
Benign
0.29
DANN
Benign
0.14
PhyloP100
-1.3
Mutation Taster
=100/0
polymorphism (auto)

Splicing

Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
0.0
Details are displayed if max score is > 0.2

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

Other links and lift over

dbSNP: rs11076785; hg19: chr16-3790186; API